WUXI BIOLOGICS AND PHANES ANNOUNCE STRATEGIC PARTNERSHIP
Shanghai and San Diego, Dec. 14, 2017 — WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Phanes Therapeutics, Inc. (Phanes), an innovative drug discovery company based in San Diego, announced today that an MOU was signed to form a strategic biologics development and manufacturing partnership.
Under the partnership, WuXi Biologics will be the clinical manufacturer for multiple biologics molecules for Phanes worldwide. WuXi Biologics will also be Phanes’ preferred partner to manufacture potential new products.
Dr. Ming Wang, President and CEO of Phanes Therapeutics, expressed enthusiasm about this partnership, “We are an innovative drug discovery company with a robust pipeline and need access to top notch CMC capabilities to quickly advance our lead molecules. We are very glad to partner with WuXi Biologics; they have a remarkable CMC capability and good track record in delivering high quality GMP materials. Their biologics CMC platform is a perfect match for us. This will allow us to continue to focus on what we do best – building innovation in research stage. We look forward to a productive partnership.”
“We are honored to enable global innovative biotechnology companies such as Phanes Therapeutics to expedite their biologics molecules into the clinic,” said Dr. Chris Chen, CEO of WuXi Biologics. “Through our global quality and integrated biologics platform, we strive to make life-saving biologics more affordable and available to global patients.”
About Phanes Therapeutics
Phanes Therapeutics is a biotech company with a portfolio in metabolic complications and oncology. It was founded by former Janssen/J&J Vice President Ming Wang, PhD, MBA. The company focuses exclusively on biologics drug discovery with multiple first-in-class molecules in its pipeline. For more information on Phanes, please visit www.phanesthera.com.
About WuXi Biologics
WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.